Table 1. Characteristics of the study population at enrollment into the cohort.

	HICs with immune progression (n = 10)	HICs with virologic progression (n = 5)	Non-progressor HICs (n = 202)
Male gender, n (%)	3 (30)	3 (60)	98 (48,5)
Age (years)	48 [43–56]	34 [32–34]***	45 [39–50]
Duration of known HIV infection (years)	18 [13–23]	5 [5–8] ***	13 [8–20]
HLA B57+ (%)	3/9 (33)	1/5 (20)	65/165 (39,4)
HCV+ status, n (%)	3 (30)	1 (20)	44 (22,8)
CD4+ T cell nadir (/mm3)	245.5 [220.3–259.8] ***	433 [405.8–455.8]	496 [376–657.5)
CD4+ T cell count (/mm3)	416.5 [296–435] ***	643 [527–1447]	763.5 [559.3–950.3]
Ultrasensitive HIV RNA (copies/mL)	117 [12–274]**	118 [78–1023]**	34 [11–89]
Total HIV DNA (copies/106 PBMCs)	11 [11–21]	42.5 [31.5–66.3]*	11 [10–46]
% of detectable VLs during history	35 [17–52] *	32 [17–47]	21 [18–25]

Results are quoted as the median [IQR] or as a percentage. All comparisons were performed relative to the group of non-progressor HICs.

*: p<0.05

**: p<0.01

***: p<0.001